Atlas Venture divests six life science portfolio firms

Omega Fund, a newly-founded direct secondary investor specialising in the healthcare sector, together with Atlas Venture, has announced the completion of a secondary transaction involving six life sciences companies in Europe and the US. Atlas Venture has sold its remaining holdings in Cropdesign NV, DeveloGen AG, Entomed SA, Micromet AG, Nitromed Inc and VascA Inc, to Omega Fund. This is the first such deal for both firms, and represents one of the first transactions in which an early-stage venture capital firm has sold a portfolio of private and public legacy positions.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Healthcare